Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Hutchison MediTech Forms Drug Distribution JV with Sinopharm

publication date: Dec 18, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison China MediTech (Chi-Med) will form a drug distribution JV with Sinopharm, investing $9.8 million to buy majority control (51%) of a Sinopharm subsidiary, HuYong Pharmaceutical (Shanghai). Chi-Med intends to use the JV to distribute its own drug products and to provide distribution/marketing services to other pharmas. More details....

Stock Symbols: (AIM: HCM) (HK: 1099)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...